Insider · CIK 0002131747
Ahmed Jamaloodeen
presidentchairofficerowner
Files at TXTM (ProText Mobility, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2022 | TXTM ProText Mobility, Inc. | AGrant or award Series D Preferred Stock | +66,667 | $0.00 | $67 | 66,667 | 4 d ago |
| Jun 3, 2022 | TXTM ProText Mobility, Inc. | AGrant or award Series A Preferred Stock | +33,333 | $0.00 | $33 | 33,333 | 4 d ago |
| Dec 31, 2024 | TXTM ProText Mobility, Inc. | POpen-market purchase Common Stock | +89,866,874 | - | - | 202,366,874 | 4 d ago |
| Sep 30, 2025 | TXTM ProText Mobility, Inc. | POpen-market purchase Common Stock | +7,170,075 | - | - | 209,536,949 | 4 d ago |
| Apr 7, 2026 | TXTM ProText Mobility, Inc. | POpen-market purchase Common Stock | +45,212,287 | - | - | 254,749,236 | 4 d ago |
| May 20, 2026 | TXTM ProText Mobility, Inc. | POpen-market purchase Common Stock | +520,905,768 | - | - | 775,655,004 | 4 d ago |
| Oct 6, 2026 | TXTM ProText Mobility, Inc. | POpen-market purchase Common Stock | +55,646,456 | - | - | 831,301,460 | 4 d ago |
| Jun 3, 2022 | TXTM ProText Mobility, Inc. | AGrant or award Series D Convertible Preferred Stockderivative | +66,667 | $0.00 | $67 | 66,667 | 4 d ago |
| Jun 3, 2022 | TXTM ProText Mobility, Inc. | AGrant or award Series A Convertible Preferred Stockderivative | +33,333 | $0.00 | $33 | 33,333 | 4 d ago |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.